TipRanks
Advertisement

DE:6BSA ETF Price & Analysis

Compare

6BSA ETF Chart & Stats

€33.01
--
Market closed
€33.01
--

ETF Overview

Virtus LifeSci Biotech Clinical Trials ETF

The Virtus LifeSci Biotech Clinical Trials ETF (Ticker: BBC) offers investors a dynamic opportunity to tap into the burgeoning world of biotechnology, specifically focusing on companies engaged in clinical trials. As a sector-focused exchange-traded fund, BBC zeroes in on the Health Care industry with a specialized emphasis on Life Sciences Tools & Services, a niche that plays a pivotal role in the advancement of medical research and innovation. BBC is meticulously designed to capture the potential growth of biotech firms that are at the forefront of developing groundbreaking therapies and medical solutions. These companies are often involved in the crucial stages of clinical trials, where promising new drugs and treatments are tested for safety and efficacy. By investing in such enterprises, the ETF provides exposure to a segment of the market that is not only essential to the healthcare ecosystem but also poised for significant advancements and breakthroughs. Investors in the Virtus LifeSci Biotech Clinical Trials ETF can expect to benefit from the rapid technological and scientific progress within the life sciences sector, making it an attractive option for those seeking to diversify their portfolios with a forward-looking, innovation-driven investment. The fund's strategic focus on clinical trials positions it uniquely within the healthcare landscape, offering both the excitement of cutting-edge scientific discovery and the potential for substantial financial returns.

Virtus LifeSci Biotech Clinical Trials ETF (6BSA) Fund Flow Chart

Virtus LifeSci Biotech Clinical Trials ETF (6BSA) 1 year Net Flows: €13M

6BSA ETF News

6BSA ETF FAQ

What was DE:6BSA’s price range in the past 12 months?
DE:6BSA lowest ETF price was €24.86 and its highest was €34.71 in the past 12 months.
    What is the AUM of DE:6BSA?
    As of Oct 13, 2026 The AUM of DE:6BSA is 40.88M.
      Is DE:6BSA overvalued?
      According to Wall Street analysts DE:6BSA’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
        Does DE:6BSA pay dividends?
        DE:6BSA does not currently pay dividends.
        How many shares outstanding does DE:6BSA have?
        Currently, no data Available
        Which hedge fund is a major shareholder of DE:6BSA?
        Currently, no hedge funds are holding shares in DE:6BSA

        6BSA ETF Smart Score

        For ETFs, the calculations for the Smart Score, Analyst Consensus, Price Target, Blogger Sentiment, News Sentiment and Insider Transactions are based on the weighted average of the ETF's holdings and some additional factors. Hedge Fund Trend, Crowd Wisdom and Technicals are based on the actual ETF ticker.​

        Top 10 Holdings

        Name
        Weight %
        Kodiak Sciences
        2.26%
        Abcellera Biologics, Inc.
        1.87%
        Xencor Inc.
        1.58%
        First Tracks Biotherapeutics Inc
        1.50%
        Amylyx Pharmaceuticals, Inc.
        1.46%
        Sellas Life Sciences Group
        1.18%
        Vaxcyte, Inc.
        1.15%
        4D Molecular Therapeutics, Inc.
        1.14%
        Replimune Group
        1.14%
        MBX Biosciences, Inc.
        1.14%
        Total14.42%
        See All Holdings
        Popular ETFs
        What am I Missing?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis
        Advertisement